Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results, Beats Expectations By $0.64 EPS

Xilio Therapeutics (NASDAQ:XLO) announced its earnings results on Tuesday. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.64, FiscalAI reports. Xilio Therapeutics had a negative net margin of 34.06% and a negative return on equity of 71.99%. The business had revenue of $9.98 million during the quarter, compared to the consensus estimate of $4.92 million.

Xilio Therapeutics Trading Up 0.4%

XLO stock traded up $0.04 during trading on Tuesday, reaching $9.04. The stock had a trading volume of 1,686 shares, compared to its average volume of 32,398. The stock’s 50 day moving average is $8.75 and its two-hundred day moving average is $8.50. The firm has a market cap of $59.48 million, a PE ratio of -5.51 and a beta of -0.13. Xilio Therapeutics has a 52 week low of $6.47 and a 52 week high of $11.30.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on XLO shares. Weiss Ratings upgraded Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Zacks Research raised Xilio Therapeutics to a “hold” rating in a research note on Thursday, October 22nd. Finally, Raymond James Financial assumed coverage on Xilio Therapeutics in a report on Wednesday, October 21st. They set an “outperform” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Xilio Therapeutics currently has an average rating of “Hold” and an average target price of $16.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects.

Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.